GS-9876

Safety and Efficacy of Filgotinib and GS-9876 in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)

February 21, 2019

https://clinicaltrials.gov/ct2/show/NCT03134222?type=Intr&cond=Lupus&phase=012345&lupd_s=02%2F07%2F2019&lupd_d=14

Condition : Cutaneous Lupus Erythematosus

Interventions : Drug: Filgotinib; Drug: GS-9876; Drug: Filgotinib placebo; Drug: GS-9876 placebo

Sponsors : Gilead Sciences; Galapagos NV

Active, not recruiting

Safety and Efficacy of Filgotinib and GS-9876 in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)

NCT03134222

Fri, 28 Apr 2017 12:00:00 EDT

February 8, 2019

https://clinicaltrials.gov/ct2/show/NCT03285711?type=Intr&cond=Lupus&phase=012345&lupd_s=01%2F25%2F2019&lupd_d=14

Condition : Lupus Membranous Nephropathy

Interventions : Drug: Filgotinib; Drug: GS-9876; Drug: Filgotinib placebo; Drug: GS-9876 placebo

Sponsor : Gilead Sciences

Active, not recruiting

Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)

NCT03285711

Mon, 18 Sep 2017 12:00:00 EDT

>>> updated February 8, 2019